Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Flucytosine
Drug ID BADD_D00913
Description A fluorinated cytosine analog that is used as an antifungal agent.
Indications and Usage For the treatment (in combination with amphotericin B) of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections).
Marketing Status approved; investigational
ATC Code D01AE21; J02AX01
DrugBank ID DB01099
KEGG ID D00323
MeSH ID D005437
PubChem ID 3366
TTD Drug ID D0S5WG
NDC Product Code 59348-0016; 63629-2148; 73309-270; 42494-339; 43386-770; 0187-3554; 63629-2147; 42973-193; 40032-771; 0187-3555; 63629-9156; 63629-9157; 0054-0428; 0904-6834; 59651-331; 59651-332; 23155-861; 43386-771; 60687-599; 0054-0427; 51927-4508; 42494-340; 50268-332; 0904-6835; 66639-008; 71666-001; 60687-610; 71052-466; 23155-860; 40032-770; 42794-009; 42794-010; 50268-331
UNII D83282DT06
Synonyms Flucytosine | 5-Fluorocytosine | Ancobon | Ancotil | Alcobon
Chemical Information
Molecular Formula C4H4FN3O
CAS Registry Number 2022-85-7
SMILES C1=NC(=O)NC(=C1F)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemoglobin13.01.05.018--Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.004--Not Available
Hypersensitivity10.01.03.003--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokalaemia14.05.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Nausea07.01.07.001--
Neuropathy peripheral17.09.03.003--Not Available
Pancytopenia01.03.03.003--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Parkinsonism17.01.05.003--Not Available
Photosensitivity reaction23.03.09.003--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Respiratory arrest22.02.01.009--Not Available
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Cardiotoxicity02.11.01.009; 12.03.01.007--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene